8-K: Genprex's Acclaim-3 Trial Advances to Phase 2 After Successful Dose Escalation

Genprex's Acclaim-3 clinical trial for Reqorsa gene therapy in combination with Tecentriq has completed its Phase 1 dose escalation, with the Safety Review Committee approving the start of Phase 2 expansion.

Summary

• Genprex has completed the Phase 1 dose escalation portion of its Acclaim-3 clinical trial.
• The trial is evaluating Reqorsa gene therapy in combination with Tecentriq for patients with extensive stage small cell lung cancer (ES-SCLC).
• The Safety Review Committee (SRC) has approved the opening of the Phase 2 expansion portion of the trial.
• The recommended Phase 2 dose of REQORSA will be 0.12 mg/kg, the highest dose level used in Phase 1.
• The Phase 2 expansion portion will enroll approximately 50 patients at 10 to 15 U.S. sites.
• Patients will receive REQORSA and Tecentriq until disease progression or unacceptable toxicity.
• The primary endpoint of Phase 2 is the 18-week progression-free survival rate.
• A futility analysis will be performed after 25 patients reach 18 weeks of follow-up.
• The trial has received FDA Fast Track and Orphan Drug Designations.

Sentiment

Score: 7

Explanation: The document conveys positive progress in the clinical trial, with no safety concerns reported and advancement to Phase 2. However, it also includes standard cautionary language about forward-looking statements and risks, which tempers the overall sentiment.

Positives

• The completion of the Phase 1 dose escalation with no dose-limiting toxicities is a positive outcome.
• The approval to move to Phase 2 indicates confidence in the safety profile of the treatment.
• The trial has received FDA Fast Track and Orphan Drug Designations, which can expedite the approval process.
• The study will be conducted at multiple sites across the US, which will help with patient recruitment.

Risks

• The success of the Phase 2 trial is not guaranteed, and results may not meet expectations.
• The company's ability to advance the clinical development, manufacturing and commercialization of its product candidates is subject to risks and uncertainty.
• The company's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern is not guaranteed.
• The company's ability to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all, is not guaranteed.

Future Outlook

The company anticipates data presentation from the Phase 1 portion of the study in 2025 and will be enrolling patients in the Phase 2 expansion portion of the trial.

Management Comments

• The company noted that it will be submitting the results of the Phase 1 portion of the study to a clinical meeting and anticipates data presentation in 2025.

Industry Context

This announcement is relevant to the oncology space, specifically in the treatment of small cell lung cancer, and highlights the ongoing research and development of novel gene therapies in combination with existing immunotherapies.

Comparison to Industry Standards

• The use of a combination therapy approach, combining a gene therapy (Reqorsa) with an immunotherapy (Tecentriq), is a growing trend in cancer treatment.
• The trial's focus on patients with extensive stage small cell lung cancer (ES-SCLC) who have progressed after initial treatment aligns with the need for new treatment options in this difficult-to-treat patient population.
• The use of progression-free survival as a primary endpoint is a common practice in oncology clinical trials.
• The FDA Fast Track and Orphan Drug Designations are consistent with the regulatory pathways for drugs targeting unmet medical needs.

Stakeholder Impact

• Shareholders may view the progress of the clinical trial positively.
• Patients with ES-SCLC may have a new treatment option if the trial is successful.
• The company's employees are likely to be impacted by the progress of the trial.

Next Steps

• The company will enroll approximately 50 patients in the Phase 2 expansion portion of the trial.
• The company will submit the results of the Phase 1 portion of the study to a clinical meeting.
• The company anticipates data presentation in 2025.
• A Phase 2 futility analysis will be performed after the 25th patient enrolled and treated reaches 18 weeks of follow up.

Key Dates

Keywords

Reqorsa, Gene Therapy, Small Cell Lung Cancer, Clinical Trial, Phase 2, Tecentriq, FDA Fast Track, Orphan Drug Designation, Oncology, Acclaim-3